Early rhythm-control ablation therapy to prevent atrial fibrillation recurrences: Insights from the CHARISMA Registry.


Journal

Pacing and clinical electrophysiology : PACE
ISSN: 1540-8159
Titre abrégé: Pacing Clin Electrophysiol
Pays: United States
ID NLM: 7803944

Informations de publication

Date de publication:
Dec 2021
Historique:
revised: 03 08 2021
received: 01 06 2021
accepted: 29 09 2021
pubmed: 5 10 2021
medline: 8 2 2022
entrez: 4 10 2021
Statut: ppublish

Résumé

An early, comprehensive rhythm-control therapy is needed in order to treat atrial fibrillation (AF) effectively and to improve ablation outcomes. A total of 153 consecutive patients from the CHARISMA registry undergoing AF ablation at eight centers were included. Patients with de novo PVI were classified as having undergone early treatment (ET) if the procedure was performed within 6 months after the first AF episode, and as having undergone delayed treatment (DT) if ablation was performed over 6 months after the first AF episode. One-hundred fifty-three patients were enrolled (69.9% male, 59 ± 10 years, 61.4% paroxysmal AF, 38.6% persistent AF). The time from the first AF episode to the ablation procedure was 1034 ± 1483 days. The ET group comprised 36 patients (25.3%), the DT group 60 (39.2%) and Redo cases were 57 (37.3%). During a mean follow-up of 366 ± 130 days, 18 patients (11.8%) suffered an AF/AT recurrence. More DT patients than ET patients suffered recurrences (15.7% vs. 2.2%, p = 0.0452) and the time to AT/AF recurrence was shorter in the group of patients who received an ablation treatment after 6 months (HR = 6.19, 95% CI: 1.7 to 21.9; p = 0.0474). On multivariate Cox analysis, only hypertension (HR = 4.86, 95% CI: 1.6 to 14.98, p = 0.0062) was independently associated with recurrences. Beyond the hypertension risk factor, ET was associated with a low risk of recurrence; recurrence rate ranged from 0% (ET patients without hypertension) to 25.0% (DT patients with hypertension). An early rhythm-control ablation therapy in the absence of common risk factors was associated with the lowest rate of recurrences.

Sections du résumé

BACKGROUND BACKGROUND
An early, comprehensive rhythm-control therapy is needed in order to treat atrial fibrillation (AF) effectively and to improve ablation outcomes.
METHODS METHODS
A total of 153 consecutive patients from the CHARISMA registry undergoing AF ablation at eight centers were included. Patients with de novo PVI were classified as having undergone early treatment (ET) if the procedure was performed within 6 months after the first AF episode, and as having undergone delayed treatment (DT) if ablation was performed over 6 months after the first AF episode.
RESULTS RESULTS
One-hundred fifty-three patients were enrolled (69.9% male, 59 ± 10 years, 61.4% paroxysmal AF, 38.6% persistent AF). The time from the first AF episode to the ablation procedure was 1034 ± 1483 days. The ET group comprised 36 patients (25.3%), the DT group 60 (39.2%) and Redo cases were 57 (37.3%). During a mean follow-up of 366 ± 130 days, 18 patients (11.8%) suffered an AF/AT recurrence. More DT patients than ET patients suffered recurrences (15.7% vs. 2.2%, p = 0.0452) and the time to AT/AF recurrence was shorter in the group of patients who received an ablation treatment after 6 months (HR = 6.19, 95% CI: 1.7 to 21.9; p = 0.0474). On multivariate Cox analysis, only hypertension (HR = 4.86, 95% CI: 1.6 to 14.98, p = 0.0062) was independently associated with recurrences. Beyond the hypertension risk factor, ET was associated with a low risk of recurrence; recurrence rate ranged from 0% (ET patients without hypertension) to 25.0% (DT patients with hypertension).
CONCLUSIONS CONCLUSIONS
An early rhythm-control ablation therapy in the absence of common risk factors was associated with the lowest rate of recurrences.

Identifiants

pubmed: 34606098
doi: 10.1111/pace.14374
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2031-2040

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Cosedis Nielsen J, Johannessen A, Raatikainen P, et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. N Engl J Med. 2012;367:1587-1595.
Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008;118:2498-2505.
D'Ascenzo F, Corleto A, Biondi-Zoccai G, et al. Which are the most reliable predictors of recurrence of atrial fibrillation after transcatheter ablation?: a meta-analysis. Int J Cardiol. 2013;167:1984-1989.
Marrouche NF, Wilber D, Hindricks G, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311:498-506.
Kuck KH, Lebedev DS, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). EP Europace. 2021;23(3):362-369.
Lycke M, Kyriakopoulou M, El Haddad M, et al. Predictors of recurrence after durable pulmonary vein isolation for paroxysmal atrial fibrillation. EP Europace. 2021;23(6):861-867.
Kirchhof P, Camm AJ, Goette A, et al. EAST-AFNET 4 trial investigators. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383:1305-1316.
Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.
Gunawardene M, Münkler P, Eickholt C, et al. A novel assessment of local impedance during catheter ablation: initial experience in humans comparing local and generator measurements. Europace. 2019;21:i34-i42.
Segreti L, De Simone A, Schillaci V, et al. A novel local impedance algorithm to guide effective pulmonary vein isolation in atrial fibrillation patients: preliminary experience across different ablation sites from the CHARISMA pilot study. J Cardiovasc Electrophysiol. 2020;31(9):2319-2327.
Martin CA, Martin R, Gajendragadkar PR, et al. First clinical use of novel ablation catheter incorporating local impedance data. J Cardiovasc Electrophysiol. 2018;29:1197-1206.
Chew DS, Black-Maier E, Loring Z, et al. Diagnosis-to-ablation time and recurrence of atrial fibrillation following catheter ablation: a systematic review and meta-analysis of observational studies. Circ Arrhythm Electrophysiol. 2020;13:e008128.
Hussein AA, Saliba WI, Barakat A, et al. Radiofrequency ablation of persistent atrial fibrillation diagnosis-to-ablation time, markers of pathways of atrial remodeling, and outcomes. Circ Arrhythm Electrophysiol. 2016;9:e003669.
Strisciuglio T, El Haddad M, Debonnaire P, et al. Paroxysmal atrial fibrillation with high vs. low arrhythmia burden: atrial remodelling and ablation outcome. Europace. 2020;22:1189-1196.
Kuppahally SS, Akoum N, Badger TJ, et al. Echocardiographic left atrial reverse remodeling after catheter ablation of atrial fibrillation is predicted by preablation delayed enhancement of left atrium by magnetic resonance imaging. Am Heart J. 2010;160:877-884.
Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J. 2008;29:1181-1189.
Healey JS, Oldgren J, Ezekowitz M, et al. Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet. 2016;388:1161-1169.
Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384(4):316-324.
Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation. N Engl J Med. 2021;384:305-315.
De With RR, Marcos EG, Dudink EAMP, et al. Atrial fibrillation progression risk factors and associated cardiovascular outcome in well-phenotyped patients: data from the AF-RISK study. EP Europace. 2020;22:352-360.
Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial fibrillation and hypertension. Hypertension. 2017;70:854-861.
Gaita F, Scaglione M, Battaglia A, et al. Very long-term outcome following transcatheter ablation of atrial fibrillation. Are results maintained after 10 years of follow up? Europace. 2018;20:443-450.
Musat DL, Milstein NS, Bhatt A, et al. Incidence and predictors of very late recurrence of atrial fibrillation following cryoballoon pulmonary vein isolation. Circ Arrhythm Electrophysiol. 2020;13:e008646.
Chelu MG, King JB, Kholmovski EG, et al. Atrial fibrosis by late gadolinium enhancement magnetic resonance imaging and catheter ablation of atrial fibrillation: 5-year follow-up data. J Am Heart Assoc. 2018;7:e006313.
Yin X, Zhao Y, Xi Y, et al. The early stage of the atrial electroanatomic remodeling as substrates for atrial fibrillation in hypertensive patients. J Am Heart Assoc. 2014;3:e001033.
Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222-2231.
Solimene F, Maddaluno F, Malacrida M, Stabile G. How to leverage local impedance to guide effective ablation strategy: a case series. HeartRhythm Case Reports. 2021;7:P65-68.

Auteurs

Francesco Solimene (F)

Clinica Montevergine, Mercogliano, Avellino, Italy.

Mario Giannotti Santoro (M)

Second Division of Cardiology, Cardiac, Thoracic, Vascular Department, New Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Giuseppe Stabile (G)

Clinica Montevergine, Mercogliano, Avellino, Italy.
Anthea Hospital, Bari, Italy.

Maurizio Malacrida (M)

Boston Scientific, Milan, Italy.

Antonio De Simone (A)

Laboratorio di Elettrofisiologia, Clinica San Michele, Maddaloni, Caserta, Italy.

Claudio Pandozi (C)

Division of Cardiology, San Filippo Neri Hospital, Rome, Italy.

Gemma Pelargonio (G)

Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Institute of Cardiology, Catholic University of Sacred Heart, Rome, Italy.

Pietro Rossi (P)

Arrhythmology Unit, Ospedale San Giovanni Calibita, Fatebefratelli, Isola Tiberina, Rome, Italy.

Alberto Battaglia (A)

Cardinal Massaia Hospital, Asti, Italy.

Domenico Pecora (D)

Electrophysiology Unit, Cardiovascular Department, Poliambulanza Institute Hospital Foundation, Brescia, Italy.

Maria Grazia Bongiorni (MG)

Second Division of Cardiology, Cardiac, Thoracic, Vascular Department, New Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Giulio Zucchelli (G)

Second Division of Cardiology, Cardiac, Thoracic, Vascular Department, New Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Camilla Stocco (C)

Boston Scientific, Milan, Italy.

Alberto Arestia (A)

Clinica Montevergine, Mercogliano, Avellino, Italy.

Sara Iuliano (S)

Laboratorio di Elettrofisiologia, Clinica San Michele, Maddaloni, Caserta, Italy.

Maurizio Russo (M)

Division of Cardiology, San Filippo Neri Hospital, Rome, Italy.

Maria Lucia Narducci (ML)

Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Luca Segreti (L)

Second Division of Cardiology, Cardiac, Thoracic, Vascular Department, New Santa Chiara Hospital, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH